摘要
目的探讨阿加曲班联合阿司匹林、氯吡格雷对进展性脑梗死患者治疗情况。方法回顾性分析我院2017年1月至2019年1月收治的进展性脑梗死患者73例,根据用药不同分为联合组(使用阿加曲班联合阿司匹林及氯吡格雷,n=39)与对照组(使用阿司匹林联合氯吡格雷,n=34),比较两组治疗前及治疗后的NIHSS、ADL评分,总有效率及不良反应发生率。结果两组治疗前NIHSS评分比较,差异无统计学意义(P>0.05),治疗5 d、10 d,联合组的NIHSS评分均低于对照组,差异有统计学意义(P<0.05);两组治疗前ADL评分比较,差异无统计学意义(P>0.05);治疗5 d、10 d后联合组的ADL评分均高于对照组,差异有统计学意义(P<0.05);联合组的临床总有效率高于对照组,差异有统计学意义(P<0.05);但两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论对进展性脑梗死患者的治疗中采用阿加曲班联合阿司匹林、氯吡格雷可降低患者神经功能的损害,提高患者的ADL评分及生活能力,不良反应较少,安全性较好。
Objective To explore the therapeutic efficacy of argatroban combined with aspirin and clopidogrel in the treatment of patients with progressive cerebral infarction.Methods A total of 73 patients with progressive cerebral infarction admitted to our hospital from January 2017 to January 2019 were retrospectively analyzed,and they were divided into the combined group(argatroban combined with aspirin and clopidogrel,n=39)and the control group(aspirin combined with clopidogrel,n=34)according to different medications.The NIHSS and ADL scores,total efficacy rates and adverse reactions(ADRs)rates of the two groups were compared before and after treatment.Results There was no statistically significant difference in NIHSS scores between the two groups before treatment(P>0.05).At 5 days,10 days of treatment,the NIHSS scores of the combined group were all lower than those of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in ADL scores between the two groups before treatment(P>0.05).At 5 days,10 days of treatment,the ADL scores of the combined group were higher than those of the control group,and the difference was statistically significant(P<0.05).The total clinical efficacy rate of the combined group was higher than that of the control group,and the difference was statistically significant(P<0.05).However,there was no statistically significant difference in the total incidences of ADRs between the two groups(P>0.05).Conclusion The application of argatroban combined with aspirin and clopidogrel in the treatment of patients with progressive cerebral infarction can reduce the damage of neurological function,improve the ADL scores and improve the living ability of patients,with fewer ADRs and better safety.
作者
宋杨君
SONG Yangjun(DepartmentⅡof Neurology,the Second Hospital of Fushun City in Liaoning Province,Fushun113001,China)
出处
《中国现代医生》
2021年第8期53-56,共4页
China Modern Doctor
